Department of General Surgery, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Department of Histology and Embryology, Guangxi Key Laboratory of Diabetic Systems Medicine, Guilin Medical University, Guilin, 541199, Guangxi, China.
Curr Pharm Biotechnol. 2024;25(15):2012-2021. doi: 10.2174/0113892010276664231228124157.
Ferroptosis is a newly discovered form of programmed cell death characterized by iron overload, ROS accumulation, and lipid peroxidation. It is distinguished by unique morphological, biochemical, and genetic features and stands apart from other known regulated cell death mechanisms. Studies have demonstrated a close association between ferroptosis and various cancers, including liver cancer, lung cancer, renal cell carcinoma, colorectal cancer, pancreatic cancer, and ovarian cancer. Inducing ferroptosis has shown promising results in inhibiting tumor growth and reversing tumor progression. However, the challenge lies in regulating ferroptosis in vivo due to the scarcity of potent compounds that can activate it. Integrating emerging biomedical discoveries and technological innovations with conventional therapies is imperative. Notably, considerable progress has been made in cancer treatment by leveraging immunotherapy and nanotechnology to trigger ferroptosis. This review explores the relationship between ferroptosis and emerging immunotherapies and nanotechnologies, along with their potential underlying mechanisms, offering valuable insights for developing novel cancer treatment strategies.
铁死亡是一种新发现的细胞程序性死亡形式,其特征为铁过载、ROS 积累和脂质过氧化。它具有独特的形态、生化和遗传特征,与其他已知的细胞死亡调控机制不同。研究表明,铁死亡与多种癌症密切相关,包括肝癌、肺癌、肾细胞癌、结直肠癌、胰腺癌和卵巢癌。诱导铁死亡在抑制肿瘤生长和逆转肿瘤进展方面显示出良好的效果。然而,由于缺乏能够激活铁死亡的有效化合物,在体内调节铁死亡仍然是一个挑战。将新兴的生物医学发现和技术创新与传统疗法相结合至关重要。值得注意的是,免疫疗法和纳米技术在触发铁死亡方面的应用为癌症治疗带来了显著进展。本综述探讨了铁死亡与新兴的免疫疗法和纳米技术之间的关系,以及它们潜在的作用机制,为开发新的癌症治疗策略提供了有价值的见解。